Your browser doesn't support javascript.
loading
Development of Neutralization Breadth against Diverse HIV-1 by Increasing Ab-Ag Interface on V2.
Gao, Nan; Gai, Yanxin; Meng, Lina; Wang, Chu; Wang, Wei; Li, Xiaojun; Gu, Tiejun; Louder, Mark K; Doria-Rose, Nicole A; Wiehe, Kevin; Nazzari, Alexandra F; Olia, Adam S; Gorman, Jason; Rawi, Reda; Wu, Wenmin; Smith, Clayton; Khant, Htet; de Val, Natalia; Yu, Bin; Luo, Junhong; Niu, Haitao; Tsybovsky, Yaroslav; Liao, Huaxin; Kepler, Thomas B; Kwong, Peter D; Mascola, John R; Qin, Chuan; Zhou, Tongqing; Yu, Xianghui; Gao, Feng.
Afiliación
  • Gao N; National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin Province, 130012, China.
  • Gai Y; National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin Province, 130012, China.
  • Meng L; National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin Province, 130012, China.
  • Wang C; National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin Province, 130012, China.
  • Wang W; Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences, Beijing, 100021, China.
  • Li X; Comparative Medicine Center, Peking Union Medical College, Beijing, 100021, China.
  • Gu T; Department of Medicine, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Louder MK; National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin Province, 130012, China.
  • Doria-Rose NA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Wiehe K; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Nazzari AF; Duke University Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Olia AS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Gorman J; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Rawi R; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Wu W; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Smith C; Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD, 21701, USA.
  • Khant H; Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD, 21701, USA.
  • de Val N; Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD, 21701, USA.
  • Yu B; Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD, 21701, USA.
  • Luo J; National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin Province, 130012, China.
  • Niu H; Institute of Molecular and Medical Virology, School of Medicine, Jinan University, Guangzhou, Guangdong Province, 510632, China.
  • Tsybovsky Y; Institute of Molecular and Medical Virology, School of Medicine, Jinan University, Guangzhou, Guangdong Province, 510632, China.
  • Liao H; Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD, 21701, USA.
  • Kepler TB; Institute of Molecular and Medical Virology, School of Medicine, Jinan University, Guangzhou, Guangdong Province, 510632, China.
  • Kwong PD; Department of Microbiology, Boston University, Boston, MA, 02215, USA.
  • Mascola JR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Qin C; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Zhou T; Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences, Beijing, 100021, China.
  • Yu X; Comparative Medicine Center, Peking Union Medical College, Beijing, 100021, China.
  • Gao F; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
Adv Sci (Weinh) ; 9(15): e2200063, 2022 05.
Article en En | MEDLINE | ID: mdl-35319830
Understanding maturation pathways of broadly neutralizing antibodies (bnAbs) against HIV-1 can be highly informative for HIV-1 vaccine development. A lineage of J038 bnAbs is now obtained from a long-term SHIV-infected macaque. J038 neutralizes 54% of global circulating HIV-1 strains. Its binding induces a unique "up" conformation for one of the V2 loops in the trimeric envelope glycoprotein and is heavily dependent on glycan, which provides nearly half of the binding surface. Their unmutated common ancestor neutralizes the autologous virus. Continuous maturation enhances neutralization potency and breadth of J038 lineage antibodies via expanding antibody-Env contact areas surrounding the core region contacted by germline-encoded residues. Developmental details and recognition features of J038 lineage antibodies revealed here provide a new pathway for elicitation and maturation of V2-targeting bnAbs.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Infecciones por VIH / VIH-1 / Seropositividad para VIH Idioma: En Revista: Adv Sci (Weinh) Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Infecciones por VIH / VIH-1 / Seropositividad para VIH Idioma: En Revista: Adv Sci (Weinh) Año: 2022 Tipo del documento: Article